Canadian innovation spawns first-of-its-kind heart health probiotic, a breakthrough in cholesterol management

 

Cardioviva™ supplement clinically proven to reduce LDL cholesterol, a risk factor in heart disease

TORONTO, May 28, 2013 /CNW/ - Canadian innovation is at the heart of a new health supplement that offers a natural way to address high cholesterol, a risk factor for heart disease. Cardiovivia™ (Lactobacillus reuteri NCIMB 30242) is the first patented probiotic supplement that works through the gut and is clinically proven to reduce LDL ("bad") cholesterol and help maintain healthy levels of cholesterol in adults. Resulting from a decade of Canadian-based research and development, Cardioviva is now available across Canada and the U.S. in the form of a small, easy-to-swallow supplement.

"Cardioviva™ is a new, natural way to address one of the most prevalent health problems of our time—high cholesterol," says Dr. Mitchell Jones, Cardioviva Product Developer and Chief Scientific Officer and a leading expert in the emerging field of the human microbiome (the gut). "Cardioviva supports a balanced bile metabolism and helps maintain healthy cholesterol levels in two ways: by reducing the amount of cholesterol the body produces, and by reducing the amount of cholesterol absorbed from food." Dr. Jones adds, "Before Cardioviva, the discussion around LDL cholesterol focused on diet, exercise, and family history; the real breakthrough moment was recognizing that gut health is contributing to heart health, which changes the discussion completely."

Currently, scientific and public health leaders around the world are putting significant efforts into better understanding the microbiome and its role in human health. Cardioviva represents a breakthrough in this field—it's the first therapeutic remedy working with the microbiome that's been shown to move a recognized marker for disease (cholesterol). Heart health can be affected by the types of bacteria in the digestive system—there are trillions of different types of bacteria in the gut that aid in digestion, support immunity, and now, also play a key role in maintaining a healthy cholesterol balance.

At a time when over 40% of Canadians and 44% of Americans have high blood cholesterol, a leading cause of heart disease (which continues to be a leading cause of death for both men and women), Cardioviva is poised to have a significant impact upon heart health and could change the way millions of adults manage their cholesterol. "The first and most important steps in cholesterol management are lifestyle changes like a healthy diet, regular physical activity, and stopping smoking," says nutrition and physiology expert Chris Mohr, RD, PhD. "Additionally, Cardioviva is a natural way to fill the gap between diet, exercise, and medication."

"Cardioviva™ is a safe, natural addition to a heart-healthy diet and lifestyle," says Shazad Bukhari, COO of The Winning Combination, the Canadian-based company responsible for bringing Cardioviva to the retail market in Canada and the U.S. this year. "Many adults need help in maintaining a healthy cholesterol balance because they exceed levels recommended by doctors to help prevent heart disease. In addition, healthy people who enjoy the digestive benefits of probiotics and are also interested in maintaining healthy levels of cholesterol may benefit from Cardioviva."

The patented probiotic in Cardioviva™ is the only probiotic to have been clinically proven with peer reviewed and published research to lower total and LDL-cholesterol by 11.6% in adults with elevated cholesterol levels (also called hypercholesterolemia)1. Clinical research for Lactobacillus reuteri NCIMB 30242 (Cardioviva) was recently presented at the American Heart Association's Scientific Sessions 2012.

Cardioviva™ is now available at major retailers across Canada. The manufacturer's suggested retail price is $34.95 for a one-month supply (60 capsules).

About The Winning Combination
Founded in 1990, The Winning Combination Inc. is one of Canada's leading health and wellness organizations with a focus on manufacturing and distributing natural health products and dietary supplements, such as Cardioviva. The Winning Combination works closely with local governing regulatory bodies to ensure its products are of the highest quality and are in regulatory compliance in the markets in which it operates. Learn more about The Winning Combination at www.winning-combination.com and Cardioviva at www.mycardioviva.com.

____________________________
1 Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolemic adults. Br J Nutr. 2012 May; 107(10):1505-13. Epub 2011 Nov 9.


Image with caption: "Cardioviva, a new heart-health probiotic supplement, is now available in Canada and the United States. It is clinically proven to lower LDL "bad" cholesterol by 11.6% and help maintain healthy cholesterol levels in adults. (CNW Group/The Winning Combination)". Image available at: http://photos.newswire.ca/images/download/20130528_C2804_PHOTO_EN_27178.jpg

Image with caption: "Cardioviva, a new heart-health probiotic supplement, is now available in Canada and the United States. It is clinically proven to lower LDL "bad" cholesterol by 11.6% and help maintain healthy cholesterol levels in adults. (CNW Group/The Winning Combination)". Image available at: http://photos.newswire.ca/images/download/20130528_C2804_PHOTO_EN_27184.jpg

Image with caption: "Cardioviva, a new heart-health probiotic that is clinically proven to lower LDL ("bad") cholesterol, is now available in Canada and the United States. Dr. Mitchell Jones, Cardioviva's product developer and CSO, holds up a sample of the small, easy-to-swallow capsule. (CNW Group/The Winning Combination)". Image available at: http://photos.newswire.ca/images/download/20130528_C2804_PHOTO_EN_27180.jpg

Image with caption: "(L-R) Ryan Jones and Dr. Mitchell Jones, the Canadian team behind Cardioviva, unveiled the new probiotic supplement in Toronto this week. Cardioviva is clinically proven to lower LDL ("bad") cholesterol, a risk factor in heart disease. (CNW Group/The Winning Combination)". Image available at: http://photos.newswire.ca/images/download/20130528_C2804_PHOTO_EN_27182.jpg

SOURCE: The Winning Combination

For further information:

Media Contact: 
Sherry Lawlor
LexPR Canada
Phone: 416-574-0405
Email: slawlor@lexpr.com

Profil de l'entreprise

The Winning Combination

Renseignements sur cet organisme

CNW Enriched News Releases

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.